	US 12,419,853 B2
	Nanoparticle pharmaceutical delivery system
Kendall Killgore, St. Louis, MO (US); and John Hefti, St. Louis, MO (US)
Assigned to Adeira Pharma, LLC
Filed by ADEIRA PHARMA, LLC, St. Louis, MO (US)
Filed on Apr. 3, 2023, as Appl. No. 18/130,336.
Application 18/130,336 is a continuation of application No. 17/324,647, filed on May 19, 2021, granted, now 11,642,420.
Application 17/324,647 is a continuation of application No. 16/575,718, filed on Sep. 19, 2019, granted, now 11,058,778, issued on Jul. 13, 2021.
Prior Publication US 2023/0241246 A1, Aug. 3, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/337 (2006.01); A61K 9/51 (2006.01); A61K 31/225 (2006.01); A61K 47/14 (2017.01); A61K 47/44 (2017.01); A61K 47/68 (2017.01); A61K 47/69 (2017.01)

CPC A61K 31/337 (2013.01) [A61K 9/5192 (2013.01); A61K 31/225 (2013.01); A61K 47/14 (2013.01); A61K 47/44 (2013.01); A61K 47/6803 (2017.08); A61K 47/6855 (2017.08); A61K 47/6929 (2017.08)]

16 Claims

1. A method to form a nanoparticle pharmaceutical delivery system, the method comprising:

dissolving at least one active pharmaceutical ingredients (APIs) in at least one lipid to form a lipid/API mixture, wherein the at least one lipid comprises triacetin and safflower oil, and the volume ratio between the triacetin and the safflower oil is between about 13:4 and about 7:1;

mixing the lipid/API mixture with an aqueous buffer and at least one first surfactant to form a crude emulsion, wherein the at least one first surfactant isolates the lipid/API mixture in the aqueous buffer; and

processing the crude emulsion using high shear forces until a fine emulsion in the form of nanoparticles suspended in the aqueous buffer is achieved.